Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Comparator: metformin

Drug: Comparator: placebo (unspecified)

Drug: MK0767

Study type

Interventional

Funder types

Industry

Identifiers

NCT00543361

0767-020

2007_627

MK0767-020

Details and patient eligibility

About

The purpose of the study is to assess how MK0767, compared to Metformin, performs in lowering blood glucose levels in patients whose Type II diabetes is not controlled by diet and exercise.

Enrollment

382 patients

Sex

All

Ages

21 to 78 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients are men and non-pregnant women ages 21 to 78 years
Patients either not on antihyperglycemic medications (>8 weeks), or being treated with a single oral antihyperglycemic agent & willing to discontinue therapy for the duration of the study

Exclusion criteria

Patient has history of type 1 diabetes mellitus and or history of ketoacidosis
Patients undergoing surgery within 30 days of Visit 1
Patients taking Warfin or Warfin-like anticoagulants
Patients on a weight loss program with on-going weight loss or starting an intensive exercise program within 4 weeks of Visit 1/Week 9